ClinicalTrials.gg
TerminatedNCT02119676Updated Feb 13, 2018Results posted

Study of Ruxolitinib in Colorectal Cancer Patients

A Phase 2 interventional study of Ruxolitinib and Regorafenib in CRC (Colorectal Cancer), sponsored by Incyte Corporation. Terminated at 86 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-13.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
396
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 19 studies in Colorectal Neoplasms by Incyte Corporation — 3 open to participants now, 5 under way, 1 of them phase 3. Colorectal Neoplasms · Incyte Corporation.

Enrollment
3rd of 19
396 · median 70
Started
2014
with 1 other
Phase 2
3 of 19
1 open now
Registered
1st of 19
by date

Among the 19 studies in Colorectal Neoplasms by Incyte Corporation, this one is the 3rd largest by enrollment, is one of 2 that started in 2014, is one of 3 in phase 2, and was the 1st registered.

Colorectal Neoplasms

6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,665 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

3 of the 19 studies in Colorectal Neoplasms by Incyte Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Colorectal Neoplasms by Incyte Corporation, or all of them as a file.
02

Study summary

The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.

Read the detailed description

The study consisted of an open-label, Part 1 safety run-in (consisting of 1 to 3 cohorts of 9 subjects each), to confirm the safety of the regorafenib/ruxolitinib combination in subjects with relapsed or refractory metastatic colorectal cancer (CRC). If determined to be tolerable, Part 2 was to proceed as a randomized, double-blind study evaluating ruxolitinib or placebo in combination with regorafenib in subjects with relapsed or refractory metastatic CRC previously treated with fluoropyrimidine, oxaliplatin, and/or irinotecan based chemotherapy, an anti-vascular endothelial growth factor (VEGF) therapy and if Kirsten rat sarcoma (KRAS) wild type an anti-epidermal growth factor receptor (EGFR) therapy.

Subjects in the safety run-in received open-label ruxolitinib and regorafenib; for the randomized, double-blind portion of the study all subjects received regorafenib and either ruxolitinib or placebo in a 1:1 blinded manner. Treatment for all subjects consisted of repeating 28-day cycles. Regorafenib was self-administered for the first 21 days of each cycle, and ruxolitinib/placebo was self-administered during the entire 28-day cycle. Treatment cycles continued as long as the regimen is tolerated, and the subject does not meet the discontinuation criteria. When subjects discontinued regorafenib, ruxolitinib or placebo they remained in the study and were followed for subsequent treatment regimens which were initiated and survival.

03

Conditions studied

  • CRC (Colorectal Cancer)

Keywords

  • Metastatic Colorectal Cancer
  • Colon Cancer
  • Ruxolitinib
  • adenocarcinoma
  • regorafenib
  • Jakavi ®
  • Jakafi ®
  • Stivarga ®
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the colon or rectum that is .
  • Previous treatment with fluoropyrimidine-, oxaliplatin- and irinotecan- based chemotherapy, an anti-VEGF therapy (if no ) and if KRAS wild type and no contraindication, an anti-EGFR therapy.
  • Radiographically measurable or evaluable disease (per v1.1)
  • of ≥ 12 weeks.
  • (ECOG) performance status of 0 to 2
  • Three or more weeks have elapsed from the completion of previous treatment regimen and subjects must have recovered or be at a new stable baseline from any related toxicities.
  • Prior radiotherapy to disease sites is allowed with certain protocol-defined restrictions.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with regorafenib.
  • Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.
  • Active peptic ulcer disease, inflammatory bowel disease (eg, ulcerative colitis, Crohn's disease), diverticulitis, or other gastrointestinal conditions with increased risk of perforation or gastrointestinal bleeding.
  • Recent history (≤ 3 months) or ongoing partial or complete bowel obstruction unless due to disease under study and corrected with surgery.
  • Blood pressure ≥ 140/90 mmHg.
  • Active bleeding diathesis or history of any major bleeding (eg, requiring transfusion of red blood cells (RBCs), central nervous system (CNS) bleeding, or significant hemoptysis within 6 months of enrollment. Subjects with bleeding secondary to underlying disease (including gastrointestinal (GI) perforation or fistula) that has been corrected by surgery or alternative procedure may be included.
  • cardiac disease including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, Class II, III, or IV congestive heart failure, and arrhythmia requiring therapy.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
396 participants (actual)

Study arms

  • Experimental
    Ruxolitinib plus regorafenib

    Drug: Ruxolitinib · Drug: Regorafenib

  • Active comparator
    Placebo plus regorafenib

    Drug: Regorafenib · Drug: Placebo

Interventions

  • 5 mg tablets to be administered by mouth Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)

    Also known as: Jakafi ®, Jakavi ®

  • Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)

    Also known as: Stivarga ®

  • DrugPlacebo

    5 mg matching placebo tablets to be administered by mouth

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from randomization to death due to any cause. Participants without death observed at the time of the analysis will be censored at last date known to be alive. The median overall survival time was estimated using the Kaplan-Meier method. Overall survival was compared between treatment groups using log-rank test.

    Time frame: Baseline until death due to any cause; up to 16 months or data cut-off 11 FEB 2016.

Secondary outcomes

  1. Progression Free Survival (PFS)

    Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the Longest Diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.

    Time frame: Baseline through disease progression, or death due to any cause if sooner; up to 16 months or data cut-off 11 FEB 2016.

  2. Overall Response Rate (ORR)

    Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target and non-target lesions without new lesion; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions, non-target lesion not progressed, and no new lesion; Progressive Disease=20% increase in sum of longest diameter of target lesions, or non-target lesion progression, or identification of new lesion; Stable Disease=small changes that do not meet above criteria. ORR was defined as the proportion of participants who achieved a best response of either CR or PR. ORR=number of participants with CR or PR/number of participants randomized.

    Time frame: Baseline through end of study; up to 16 months or data cut-off 11 FEB 2016.

  3. Duration of Response

    Duration of response is defined as the time from response (CR/PR) until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause.

    Time frame: Baseline through end of study; up to 16 months or data cut-off 11 FEB 2016.

  4. Percentage of Participants Achieving Disease Control

    Disease control as measured by the percentage of participants whose best response was complete response (CR), partial response (PR), or stable disease (SD) per RECIST v.1.1.

    Time frame: Baseline through end of study; up to 16 months or data cut-off 11 FEB 2016.

  5. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)

    TEAEs were defined as any adverse event (AE) during the study that began or worsened on or after the date of first dose of investigational product.

    Time frame: Baseline through approximately 30 days post treatment discontinuation;up to 16 months or data cut-off 27JAN 2016 for Substudy 1 and up to the data cut-off of 11FEB2016 for Substudy 2.

07

Results

Posted Jun 14, 2017
Limitations and caveats
Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.

Participant flow

In Substudy 1, the first subject was enrolled on 29 OCT 2014, and the last subject was enrolled on 23 JUL 2015. In Substudy 2, the first subject was enrolled on 05 NOV 2014, and the last subject was enrolled on 02 OCT 2015.

Participant flow — Overall Study
MilestoneSubstudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + Regorafenib
Started8788110111
Treated patients8586106106
Completed421310
Not completed838697101
Withdrew: Adverse event9171010
Withdrew: Disease progression53556873
Withdrew: Patient decision, inc. consent withdrawn4556
Withdrew: Physician decision4232
Withdrew: Death9321
Withdrew: Noncompliance0100
Withdrew: Lost to follow-up0010
Withdrew: Protocol deviation0010
Withdrew: Other, unspecified2134
Withdrew: Did not receive study med2245

Outcome measures

PrimaryOverall Survival (OS)

Overall survival is defined as the time from randomization to death due to any cause. Participants without death observed at the time of the analysis will be censored at last date known to be alive. The median overall survival time was estimated using the Kaplan-Meier method. Overall survival was compared between treatment groups using log-rank test.

Time frame:
Baseline until death due to any cause; up to 16 months or data cut-off 11 FEB 2016.
Reported as:
Median · months
Overall Survival (OS)
monthsSubstudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + Regorafenib
Overall Survival (OS)4.6 (3.5 to 5.4)5.3 (4.3 to 6.0)11.4 (9.0 to 13.2)10.9 (7.2 to NA)
Statistical analysis
  • Substudy 1: Ruxolitinib + Regorafenib vs Substudy 1: Placebo + Regorafenib · Log Rank · p = 0.588 (1-sided) · Hazard ratio (hr): 1.04 · 95% CI 0.73 to 1.49Estimated using a Cox regression model with Efron's method used for ties, stratified by mGPS score and geographical region
  • Substudy 2: Ruxolitinib + Regorafenib vs Substudy 2: Placebo + Regorafenib · Log Rank · p = 0.136 (1-sided) · Hazard ratio (hr): 0.77 · 95% CI 0.48 to 1.23Estimated using Cox regression model with Efron's method used for ties, stratified by geographical region
SecondaryProgression Free Survival (PFS)

Progressive Disease (PD) is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 at least a 20% increase in the sum of the Longest Diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, unequivocal progression of non-target lesions, or the appearance of new lesions.

Time frame:
Baseline through disease progression, or death due to any cause if sooner; up to 16 months or data cut-off 11 FEB 2016.
Reported as:
Median · months
Progression Free Survival (PFS)
monthsSubstudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + Regorafenib
Progression Free Survival (PFS)2.2 (1.9 to 3.0)2.1 (1.8 to 2.7)3.5 (3.0 to 3.8)2.0 (1.9 to 3.1)
SecondaryOverall Response Rate (ORR)

Response defined per Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR)=disappearance of all target and non-target lesions without new lesion; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions, non-target lesion not progressed, and no new lesion; Progressive Disease=20% increase in sum of longest diameter of target lesions, or non-target lesion progression, or identification of new lesion; Stable Disease=small changes that do not meet above criteria. ORR was defined as the proportion of participants who achieved a best response of either CR or PR. ORR=number of participants with CR or PR/number of participants randomized.

Time frame:
Baseline through end of study; up to 16 months or data cut-off 11 FEB 2016.
Reported as:
Number · percentage of responders
Overall Response Rate (ORR)
percentage of respondersSubstudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + Regorafenib
Overall Response Rate (ORR)0.0 (0.0 to 4.2)0.0 (0.0 to 4.1)2.7 (0.6 to 7.8)4.5 (1.5 to 10.2)
SecondaryDuration of Response

Duration of response is defined as the time from response (CR/PR) until the earliest date of disease progression determined by investigator assessment of objective radiographic disease assessments per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause.

Time frame:
Baseline through end of study; up to 16 months or data cut-off 11 FEB 2016.

No measurements were reported for this outcome.

SecondaryPercentage of Participants Achieving Disease Control

Disease control as measured by the percentage of participants whose best response was complete response (CR), partial response (PR), or stable disease (SD) per RECIST v.1.1.

Time frame:
Baseline through end of study; up to 16 months or data cut-off 11 FEB 2016.
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Disease Control
percentage of participantsSubstudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + Regorafenib
Percentage of Participants Achieving Disease Control40.2 (29.9 to 51.3)34.1 (24.3 to 45.0)61.8 (52.1 to 70.9)36.9 (28.0 to 46.6)
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs)

TEAEs were defined as any adverse event (AE) during the study that began or worsened on or after the date of first dose of investigational product.

Time frame:
Baseline through approximately 30 days post treatment discontinuation;up to 16 months or data cut-off 27JAN 2016 for Substudy 1 and up to the data cut-off of 11FEB2016 for Substudy 2.
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
percentage of participantsSubstudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + Regorafenib
Participants with any TEAEs100.0100.0100.099.1
Participants with Grade 3/4 TEAEs82.481.477.472.6
Participants with any serious TEAE57.648.834.934.9
Participants with a fatal TEAE15.39.31.93.8
Participants who discontinued drug due to of TEAEs14.119.811.310.4

Adverse events

Collected over From the first dose of study medication up to 16 months or data cut-off 11 FEB 2016.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Substudy 1: Ruxolitinib + Regorafenib—49/85 (57.6%)85/85 (100%)
Substudy 1: Placebo + Regorafenib—42/86 (48.8%)86/86 (100%)
Substudy 2: Ruxolitinib + Regorafenib—37/106 (34.9%)106/106 (100%)
Substudy 2: Placebo + Regorafenib—37/106 (34.9%)105/106 (99.1%)
Most frequent serious events
Showing 10 of 143
Most frequent serious events
EventSubstudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + Regorafenib
Abdominal painGastrointestinal disorders6/857/864/1065/106
SepsisInfections and infestations6/851/861/1061/106
Hepatobiliary disordersGeneral disorders5/852/860/1060/106
PneumoniaInfections and infestations5/852/860/1060/106
Small intestinal obstructionGastrointestinal disorders2/851/860/1065/106
DyspnoeaRespiratory, thoracic and mediastinal disorders0/852/865/1061/106
General physical health deteriorationGeneral disorders4/853/861/1061/106
Blood bilirubin increasedInvestigations4/851/860/1063/106
VomitingGastrointestinal disorders2/854/863/1064/106
AnaemiaBlood and lymphatic system disorders0/850/864/1060/106
Most frequent other events
Showing 10 of 59
Most frequent other events
EventSubstudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + Regorafenib
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders36/8538/8661/10650/106
FatigueGeneral disorders29/8531/8643/10647/106
HypertensionVascular disorders18/8522/8644/10642/106
DiarrhoeaGastrointestinal disorders32/8527/8641/10629/106
Decreased appetiteMetabolism and nutrition disorders31/8531/8628/10635/106
ConstipationGastrointestinal disorders27/8521/8624/10622/106
NauseaGastrointestinal disorders22/8522/8630/10622/106
Abdominal painGastrointestinal disorders21/8524/8624/10626/106
AstheniaGeneral disorders22/8522/8619/10623/106
AnaemiaBlood and lymphatic system disorders10/8512/8627/10612/106

Baseline characteristics

The intent-to-treat (ITT) population consisted of participants that were randomized in the study.

Age, Continuous
Age, Continuous(years)Substudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + RegorafenibTotal
Mean60.8 (34.0 to 84.0)59.5 (36.0 to 81.0)59.0 (37.0 to 79.0)59.2 (19.0 to 83.0)59.6 (19 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Substudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + RegorafenibTotal
Female34324854168
Male53566257228
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Substudy 1: Ruxolitinib + RegorafenibSubstudy 1: Placebo + RegorafenibSubstudy 2: Ruxolitinib + RegorafenibSubstudy 2: Placebo + RegorafenibTotal
American Indian or Alaska Native00000
Asian0210921
Native Hawaiian or Other Pacific Islander00101
Black or African American776727
White70708480304
More than one race10951135
Unknown or Not Reported00448
08

Study locations

86 sites
  • Chandler, Arizona, United States
  • Gilbert, Arizona, United States
  • Mesa, Arizona, United States
  • Scottsdale, Arizona, United States
  • Los Angeles, California, United States
  • Pasadena, California, United States
  • Santa Barbara, California, United States
  • Aurora, Colorado, United States
  • Colorado Springs, Colorado, United States
  • Denver, Colorado, United States
  • Altamonte Springs, Florida, United States
  • Miami, Florida, United States
  • Ocala, Florida, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Niles, Illinois, United States
  • Lafayette, Indiana, United States
  • Ames, Iowa, United States
  • New Orleans, Louisiana, United States
  • Baltimore, Maryland, United States
  • Jefferson City, Missouri, United States
  • Saint Louis, Missouri, United States
  • Lincoln, Nebraska, United States
  • Omaha, Nebraska, United States
  • Henderson, Nevada, United States
  • Las Vegas, Nevada, United States
  • Albany, New York, United States
  • Binghamton, New York, United States
  • Bronx, New York, United States
  • Hudson, New York, United States
  • Johnson City, New York, United States
  • New York, New York, United States
  • Canton, Ohio, United States
  • Cincinnati, Ohio, United States
  • Portland, Oregon, United States
  • Charleston, South Carolina, United States
  • Easley, South Carolina, United States
  • Greenville, South Carolina, United States
  • Greer, South Carolina, United States
  • Sumter, South Carolina, United States
  • Chattanooga, Tennessee, United States
  • Nashville, Tennessee, United States
  • Arlington, Texas, United States
  • El Paso, Texas, United States
  • Fort Worth, Texas, United States
  • Houston, Texas, United States
  • Paris, Texas, United States
  • Plano, Texas, United States
  • Tyler, Texas, United States
  • American Fork, Utah, United States
  • Bountiful, Utah, United States
  • Murray, Utah, United States
  • Provo, Utah, United States
  • Salt Lake City, Utah, United States
  • West Jordan, Utah, United States
  • Roanoke, Virginia, United States
  • Vancouver, Washington, United States
  • Bentleigh East, Australia
  • Herston, Australia
  • Kurralta Park, Australia
  • New Lambton Heights, Australia
  • Randwick, Australia
  • Avignon Cedex 09, France
  • Besançon, France
  • Le Mans, France
  • Lille, France
  • Marseille Cedex 05, France
  • Paris, France
  • Augsburg, Germany
  • Halle, Germany
  • Hamburg, Germany
  • Beer Sheva, Israel
  • Haifa, Israel
  • Petah Tikva, Israel
  • Ramat Gan, Israel
  • Tel Aviv, Israel
  • Soeul, Korea, Republic of
  • Oviedo, Asturias, Spain
  • Barcelona, Spain
  • Madrid, Spain
  • Sevilla, Spain
  • Valencia, Spain
  • Birmingham, United Kingdom
  • Bournemouth, United Kingdom
  • London, United Kingdom
  • Sutton, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2014, a primary completion of Feb 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2014
First posted
Apr 22, 2014
Start
Mar 2014
Primary completionActual
Feb 2016
CompletionActual
Dec 2016
Results first posted
Jun 14, 2017
Last update
Feb 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02119676
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 22, 2014
Start date
Mar 2014
Primary completion
Feb 2016
Completion
Dec 2016
Results posted
Jun 14, 2017
Last update
Feb 13, 2018

Study contacts

Albert Assad
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion